NDA 017768 · Molnlycke Hlth
Hibiclens
Chlorhexidine Gluconate · Topical
Priority reviewLast checked: Nov 20, 2026Latest source record: Oct 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1976
Sep 17, 1976
Approved uses
2
Original approval plus efficacy supplements
Registered trials
551
112 Phase 3, 30 recruiting
FAERS reports
8,186
6,794 serious, 2,730 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 23, 2024.
Uses antimicrobial skin cleanser helps reduce bacteria that potentially can cause disease for skin wound and general skin cleansing surgical hand scrub healthcare personnel handwash
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 1, 1982 Supplement 2 · Efficacy
- Sep 17, 1976 Original approval · Type 2 - New Active Ingredient · priority review
1 products under this application
- HIBICLENS · CHLORHEXIDINE GLUCONATE 4% · SOLUTION, TOPICAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Chlorhexidine Gluconate" as an intervention, any sponsor and status, largest first.
- Mupirocin-Iodophor ICU Decolonization Swap Out TrialPivotal-lookingCompleted
Harvard Pilgrim Health CareAcademic, hospital or other
NCT03140423 · 353,323 participants · Start May 1, 2017 · Primary completion Nov 6, 2023
Drug: Arm 1. Routine Care (Mupirocin/CHG); Arm 2. Iodophor/CHG Decolonization · For: Staphylococcus Aureus
Sites: Riverside, California; San Jose, California; Thousand Oaks, California · 137 sites in all
- Zambia Chlorhexidine Application TrialPivotal-lookingCompleted
Boston UniversityAcademic, hospital or other
NCT01241318 · 77,535 participants · Start Feb 2011 · Primary completion Sep 2013
Drug: Chlorhexidine gluconate (4%) · For: Sepsis
Sites: Choma, Zambia
- Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)Pivotal-lookingCompleted
Harvard Pilgrim Health CareAcademic, hospital or other
NCT00980980 · 74,256 participants · Start Sep 2009 · Primary completion Sep 2011
Drug: Chlorhexidine bath and nasal mupirocin · For: Methicillin-resistant Staphylococcus Aureus
Sites: Anchorage, Alaska; Thousand Oaks, California; Aurora, Colorado · 42 sites in all
- Chlorhexidine Cordcare for Reduction in Neonatal Mortality and OmphalitisPivotal-lookingCompleted
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
NCT01528852 · 36,911 participants · Start May 19, 2011 · Primary completion Sep 29, 2014
Drug: Chlorhexidine 4%; Chlorhexidine 4% · For: Neonatal Mortality; Cord Care; Omphalitis
Sites: Pemba, Tanzania
- Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military TraineesPivotal-lookingCompleted
Henry M. Jackson Foundation for the Advancement of Military MedicineAcademic, hospital or other
NCT01105767 · 30,209 participants · Start May 2010 · Primary completion Jan 2012
Drug: Chlorhexidine gluconate · For: Staphylococcus Aureus; MRSA Skin Infections; Staphylococcal Skin Infections
Sites: Columbus, Georgia
VA Office of Research and DevelopmentFederal agency
NCT02216227 · 23,005 participants · Start Apr 1, 2014 · Primary completion Feb 28, 2021
Drug: Mupirocin; Chlorhexidine gluconate and 3 more · For: Surgical Site Infection
Sites: Miami, Florida; Iowa City, Iowa; Baltimore, Maryland · 11 sites in all
- Infection Prophylaxis in Total Joint ReplacementPivotal-lookingRecruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06126614 · 21,006 participants (planned) · Start May 7, 2024 · Primary completion Nov 2028
Drug: Chlorhexidine Gluconate; Vancomycin Hydrochloride · For: Periprosthetic Joint Infection
Sites: Hamilton, Canada
- Project PROTECT: Protecting Nursing Homes From Infections and HospitalizationPivotal-lookingCompleted
University of California, IrvineAcademic, hospital or other
NCT03118232 · 13,952 participants · Start Apr 3, 2017 · Primary completion Oct 10, 2023
Drug: Chlorhexidine gluconate (CHG); Iodophor (10% povidone-iodine) · For: Hospitalization; Infection
Sites: Anaheim, California; Bellflower, California; Capistrano Beach, California · 28 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue1,922
- joint swelling1,726
- rash1,724
- hypersensitivity1,677
- impaired healing1,635
- pain1,631
- folliculitis1,621
- weight increased1,613
- stomatitis1,569
- arthralgia1,568
- lower respiratory tract infection1,543
- off label use1,539
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 30 |
| 2005 | 22 |
| 2006 | 30 |
| 2007 | 40 |
| 2008 | 94 |
| 2009 | 104 |
| 2010 | 160 |
| 2011 | 165 |
| 2012 | 180 |
| 2013 | 77 |
| 2014 | 92 |
| 2015 | 149 |
| 2016 | 281 |
| 2017 | 290 |
| 2018 | 332 |
| 2019 | 351 |
| 2020 | 439 |
| 2021 | 702 |
| 2022 | 625 |
| 2023 | 536 |
| 2024 | 1,343 |
| 2025 | 1,570 |
| 2026 | 574 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Improving central venous catheter care with chlorhexidine gluconate dressings: evidence from a systematic review and Meta-analysis.
Xu H, Zhu M, Xu S, et al. · J Health Popul Nutr 2024 · Systematic Review, Meta-Analysis
- Bathing with wipes impregnated with chlorhexidine gluconate to prevent central line-associated bloodstream infection in critically ill patients: A systematic review with meta-analysis.
Peixoto EAC, Poveda VB, Gnatta JR, et al. · Am J Infect Control 2024 · Systematic Review, Meta-Analysis
- Povidone Iodine vs Chlorhexidine Gluconate in Alcohol for Preoperative Skin Antisepsis: A Randomized Clinical Trial.
Widmer AF, Atkinson A, Kuster SP, et al. · JAMA 2024 · Comparative Study, Equivalence Trial
- The effectiveness of dressings and securement devices to prevent central venous catheter-associated complications: A systematic review and meta-analysis.
Xu H, Hyun A, Mihala G, et al. · Int J Nurs Stud 2024 · Meta-Analysis, Systematic Review
- The Comparative Efficacy of Chlorhexidine Gluconate and Povidone-iodine Antiseptics for the Prevention of Infection in Clean Surgery: A Systematic Review and Network Meta-analysis.
Wade RG, Burr NE, McCauley G, et al. · Ann Surg 2021 · Comparative Study, Research Support, Non-U.S. Gov't
- Prevention Strategies for Neonatal Skin Injury in the NICU.
Behr JH, Wardell D, Rozmus CL, et al. · Neonatal Netw 2020 · Systematic Review
Sponsor: Molnlycke Hlth
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.